Ipamorelin

Original price was: $49.99.Current price is: $44.99.

Research Overview of a Selective Growth Hormone Secretagogue

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a). Research examines its ability to stimulate endogenous growth hormone release.

Mechanism of Action in Research Settings

Ipamorelin binds the GHS-R1a receptor, the same target activated by the endogenous hormone ghrelin, on pituitary somatotroph cells. Activation triggers intracellular signaling that promotes release of stored growth hormone in a pulsatile manner. Studies describe this pathway as independent of the growth hormone-releasing hormone axis, allowing examination of additive effects in research models.

Unlike certain related growth hormone-releasing peptides, Ipamorelin demonstrates high selectivity in animal models. Research reports minimal concurrent stimulation of adrenocorticotropic hormone, cortisol, or prolactin at doses effective for growth hormone release. This selectivity profile forms a primary focus of early characterization studies. Human pharmacokinetic data confirm a short-lived growth hormone pulse following administration in controlled settings.

Available Research Data on Ipamorelin

Published human evidence remains limited. A pharmacokinetic-pharmacodynamic study in healthy volunteers characterized dose-related growth hormone release, with peak effects occurring relatively soon after dosing and a terminal half-life of approximately two hours. Separate phase 2 investigation evaluated intravenous administration for postoperative ileus recovery after bowel surgery. That randomized, placebo-controlled trial did not meet its primary efficacy endpoint regarding time to tolerance of solid meals.

Preclinical work in animal models has explored additional endpoints, including longitudinal bone growth and effects on gastrointestinal transit. These findings remain confined to laboratory contexts and do not translate directly to established clinical applications. No large-scale, long-term randomized trials exist for outcomes frequently discussed outside formal research, such as body composition changes or recovery metrics in healthy populations.

Regulatory and Research Status

Ipamorelin holds no approval from the U.S. Food and Drug Administration or equivalent regulatory bodies for any medical indication. It appears in research chemical contexts and has been subject to review under compounding policies due to limited safety characterization for certain routes and concerns noted in available literature. The compound is prohibited under World Anti-Doping Agency rules for athletic use.

Safety information derives primarily from short-term trial data and class effects associated with growth hormone elevation. Reported observations in controlled settings include gastrointestinal symptoms and laboratory changes in some participants. Theoretical considerations linked to growth hormone and IGF-1 pathways include potential influences on glucose handling and fluid balance. Long-term human safety data beyond limited trial durations are not available in the published record.

Key Considerations for Research Contexts

Investigators examining Ipamorelin typically reference its receptor selectivity and pharmacokinetic profile when designing experiments involving the growth hormone axis. Quality control, purity verification, and adherence to research-use designations remain standard requirements in laboratory settings. Any discussion of this peptide occurs strictly within the framework of scientific inquiry rather than clinical recommendation.

Reviews

There are no reviews yet.

Be the first to review “Ipamorelin”

Your email address will not be published. Required fields are marked *